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 Dysregulation of lipid metabolism is closely related with 
a number of pathological states including atherosclerosis, 
obesity, and insulin resistance. An extensive amount of 
data relates elevation of cholesterol and triglycerides (TG) 
in apolipoprotein (apo)B-containing particles such as 
VLDL and LDL to increased risk for atherosclerosis. Epi-
demiological and clinical studies have provided strong evi-
dence that a low level of cholesterol in HDL is also a major 
risk factor for the development of atherosclerosis ( 4, 5 ). 
LPL is a key molecule involved in the hydrolysis of TG in 
VLDL and chylomicrons and in the clearance of these par-
ticles from circulation ( 6 ). In vitro observations as well as 
animal models have fi rmly established ANGPTL 3 and 4 as 
potent inhibitors of LPL ( 7, 8 ). These studies are sup-
ported by genetic studies in humans that have associated 
mutations in these two proteins with circulating TG levels 
( 9–11 ). Endothelial lipase (EL), a member of the triglycer-
ide lipase gene family, has been demonstrated to infl u-
ence the levels of HDL in circulation ( 12 ). Recently, it was 
shown that ANGPTL3 can inhibit EL and thereby increase 
the levels of HDL ( 13 ). 
 Epidemiological studies clearly demonstrate that obesity 
has increased worldwide. Obesity increases the risk of dia-
betes, heart disease, fatty liver, and even some forms of can-
cer. It is therefore important to better understand the 
biological basis of obesity in order to aid its prevention 
and treatment. Several studies in mice have shown that 
ANGPTL4 can act as a powerful signal from adipose and 
other tissues to prevent fat storage and stimulate fat mobi-
lization ( 14, 15 ). There is a large body of evidence demon-
strating that ANGPTL 3 and 4 play major roles in rodent 
energy metabolism. However, there is limited information 
on the physiological roles of ANGPTL 3 and 4 in humans. 
 Abstract  We have developed and validated quantitative 
ELISAs for human angiopoietin-like (ANGPTL)3 and 4 and 
correlated their serum levels with parameters of lipid and 
carbohydrate metabolism. For this study, we used a random 
subsample of the Health 2000 Health Examination Survey 
consisting of 125 men and 125 women, aged 30–94 years. 
The anthropometric and biochemical parameters of sub-
jects were characterized in detail. ANGPTL 3 and 4 levels 
were determined using the developed ELISAs. The intra- 
and inter-assay coeffi cients of variation for the assays were 
less than 15%. The average serum concentration of 
ANGPTL3 was 368 ± 168 ng/ml (mean ± SD) and for 
ANGPTL4 it was 18 ± 23 ng/ml (mean ± SD). ANGPTL4 
serum levels displayed high variability between individuals 
ranging from 2 to 158 ng/ml. In post-heparin plasma, both 
ANGPTL 3 and 4 were increased. Low levels of ANGPTL3 
were associated with decreased HDL-cholesterol and in-
creased triglyceride levels. ANGPTL4 levels were positively 
correlated with FFAs ( P = 0.044) and waist-hip ratio ( P = 
0.016).  The developed ELISAs will be important tools to 
clarify the role of ANGPTL 3 and 4 in human energy me-
tabolism and partitioning of triglycerides between sites of 
storage (adipose tissue) and oxidation (skeletal and cardiac 
muscle). —Robciuc, M. R., E. Tahvanainen, M. Jauhiainen, 
and C. Ehnholm.  Quantitation of serum angiopoietin-like 
proteins 3 and 4 in a Finnish population sample.  J. Lipid Res . 
2010.  51: 824–831. 
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 Angiopoietin-like (ANGPTL) proteins 3 and 4 belong 
to a family of proteins that share a common modular struc-
ture consisting of an N-terminal signal sequence, a coiled-
coil domain and a large fi brinogen/angiopoietin-like 
domain ( 1, 2 ). Recently, ANGPTL 3 and 4 have emerged 
as important modulators of lipid metabolism ( 3 ). 
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The plate was washed four times with PBS-Tw (50 mM potassium 
phosphate 150 mM NaCl, 0.1% Tween 20; pH 7.4) on the Well-
wash AC (Thermo Scientifi c). Nonspecifi c binding sites were 
blocked with 300   l/well of 0.5% BSA (w/v) in PBS for 2 h at 
room temperature. After aspiration, samples and standards were 
diluted with TBS (0.05 mM Tris-HCl, 0.15 mM NaCl, pH 7.6 con-
taining 0.1% BSA (w/v) and 0.1% Tween 20) and were pipetted 
in duplicates (100   l/well). The plate was incubated for 1 h at 
room temperature. After washing four times with 350 µl/well 
PBS-Tw, detection antibody was added 100   l/well (0.2   g/ml) 
and the plate was incubated for 1 h at room temperature. Follow-
ing four washes, streptavidin-HRP (streptavidin conjugated to 
horseradish-peroxidase), diluted 1: 200 in PBS, 1% BSA (w/v) 
was added (100   l/well) and the plate was incubated for 30 min 
at room temperature. After washing, 3, 3 ′ , 5, 5 ′ tetramethylbenzi-
dine (TMB) substrate (Sigma) was added (100   l/well) and the 
plate incubated for another 4–6 min at room temperature. The 
reaction was stopped with 1 N sulfuric acid, 100   l/well. The de-
veloped color was determined by reading the plate on the mi-
croplate reader Victor 2 Multilabel Counter (Wallac, Turku, 
Finland) at a wavelength of 450 nm. Standards were prepared at 
concentrations of 1.25, 2.5, 5, 10, 20, and 40 ng/ml. For stan-
dardization, we used a human serum quantifi ed for ANGPTL3 
with a commercially available kit from BioVendor following the 
manufacturer’s instructions. The standardized serum was stored 
at –70°C in small aliquots and for every measurement a new ali-
quot was thawed. The serum samples were diluted 50-fold. The 
standard curve was constructed by plotting the concentration 
(X) of standards against the mean absorbance (Y) of standards at 
450 nm ( Fig. 1A ). A second order polynomial equation was used 
to fi t the standards and calculate the sample concentrations. 
 Determination of ANGPTL4 concentration 
 To measure the concentration of human ANGPTL4 in circula-
tion we have developed a noncompetitive direct ELISA using the 
DuoSet Elisa hANGPTL4 (RnD Systems) and the protocol de-
scribed by Kersten et al. with some modifi cations ( 21 ). We used 
the goat anti-human ANGPTL4 as a capture antibody to coat 96-
well plates, 100   l/well (1.6   g/ml in PBS) overnight at 4°C. The 
plate was washed four times with PBS-Tw (50 mM potassium 
phosphate 150 mM NaCl, 0.1% Tween 20; pH 7.4) on the Well-
wash AC (Thermo Scientifi c). Nonspecifi c binding sites were 
blocked with 300   l/well of 0.5% BSA (w/v) in PBS for 2 h at 
room temperature. After aspiration, samples and standards (hu-
man recombinant ANGPTL4) diluted with TBS (0.05 mM Tris-
HCl, 0.15 mM NaCl, pH 7.6) containing 0.1% BSA (w/v) and 
0.05% Tween 20 were pipetted in duplicates (100   l/well). The 
plate was incubated for 1 h at room temperature. After four 
washes with PBS-Tw, 100   l/well (0.2   g/ml) of detection anti-
body (biotinylated goat anti-human ANGPTL4) was added and 
the plate was incubated for 1 h at room temperature. Following 
four washes, 100   l/well of streptavidin-HRP diluted 1:200 in 
PBS, 1% BSA (w/v) was added and the plate was incubated for 30 
min at room temperature. After washing, 100   l/well TMB sub-
strate was added and the plate was incubated for another 4–6 min 
at room temperature. The reaction was stopped with 100   l/well 
of 1 N sulfuric acid. The plates were analyzed using the mi-
croplate reader Victor 2 Multilabel Counter (Wallac) at 450 nm. 
Standards were prepared at concentrations of 0.19, 0.39, 0.78, 
1.56, 3.12, 6.25, 12.5, and 25 ng/ml. Serum samples were diluted 
1: 10 and samples exceeding the highest absorbance of the stan-
dard curve were diluted further 1: 20 or 1: 40. The standard curve 
was constructed by plotting the concentration (X) of standards 
against the mean absorbance (Y) of standards at 450 nm ( Fig. 
1B ). A second order polynomial equation was used to fi t the stan-
dards and calculate the sample concentration. 
 In order to increase our knowledge concerning the 
roles of ANGPTL 3 and 4 in human physiology, we devel-
oped methods to measure circulating levels of these pro-
teins. The present study reports on the measurements of 
serum ANGPTL 3 and 4 in a normal Finnish population 
sample and correlates their plasma levels to parameters of 
lipid and carbohydrate metabolism. 
 MATERIALS AND METHODS 
 Subjects 
 For this study we used a random subsample of the Health 2000 
Health Examination Survey carried out in Finland consisting of 
250 subjects (125 men and 125 women), age range 30–94 years 
( 16, 17 ). Serum samples (1.5 ml aliquots) were stored at –70°C 
before analysis. To evaluate the effect of heparin on the levels of 
ANGPTL 3 and 4, seven volunteers received a heparin injection 
(100 IU/kg body weight) and post-heparin plasma was collected 
after 15 min. ANGPTL 3 and 4 were measured in pre- and post-
heparin plasma. For kinetic studies, three volunteers received a 
heparin injection (100 IU/kg body weight) and plasma samples 
were collected at 0, 5, 10, 15, 30, and 60 min after injection and 
levels of ANGPTL4 were assessed. Each study subject gave written 
informed consent before participating in the study. The samples 
were collected in accordance with the Helsinki Declaration and 
ethics committees of the participating centers approved the 
study design. 
 General procedures 
 Protein concentration was determined by the method of Lowry 
et al. ( 18 ). ApoA-I, apoA-II, and apoB concentrations were mea-
sured by immunoturbidometric methods using commercial kits 
(Orion Diagnostica, Espoo, Finland; Boehringer-Mannheim, 
Mannheim, Germany) using an automatic clinical chemistry ana-
lyzer (Olympus Diagnostica GmbH). Serum total cholesterol 
(TC) and TG were analyzed using fully enzymatic methods 
(Olympus Diagnostica). Serum FFAs were quantifi ed using a kit 
from Zen-Bio, Inc. (Research Triangle Park, NC). HDL- and 
LDL-cholesterol (HDL-C, LDL-C) were measured using direct 
enzymatic methods (Roche Diagnostics GmbH). Plasma glucose 
concentration was analyzed by a hexokinase method (Olympus 
Diagnostica), and insulin was analyzed by a microparticle enzyme 
immunoassay (Abbott Diagnostics Division, Axis-Shield, Oslo, 
Norway). Concentration of C-reactive protein (CRP) was deter-
mined by an immunoturbidometric method (Orion Diagnos-
tica). Serum homocysteine (Hcy) was measured using the 
high-pressure liquid chromatographic method ( 19 ). The homeo-
stasis model assessment for insulin resistance (HOMA IR) was 
calculated from the fasting plasma glucose and serum insulin 
concentrations as follows: fasting insulin (µU/ml) × fasting glu-
cose (mmol/l)/22.5 ( 20 ). Physical activity of the subjects was as-
sessed by questionnaire and divided in four categories: ideal, 
suffi cient, uncertain, and insuffi cient. 
 Determination of ANGPTL3 concentration 
 We developed a noncompetitive ELISA to determine the con-
centration of human serum/plasma ANGPTL3. As a capture an-
tibody, we used a rabbit polyclonal antibody raised against 
recombinant ANGPTL3 (aa 17-223) (BioVendor, Czech Repub-
lic) and as a detection antibody, a biotinylated sheep IgG raised 
against human recombinant ANGPTL3 (aa 17-460) (RnD Sys-
tems, Minneapolis, MN). The capture antibody was used to coat 
96-well plates, 100   l/well (1   g/ml in PBS) overnight at 4°C. 
 at Terkko - N
ational Library of Health Sciences, on M
ay 16, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
826 Journal of Lipid Research Volume 51, 2010
formed before they were used in statistical analyses. To determine 
the relationship between serum levels of ANGPTL 3 and 4 and 
other measured parameters, the Pearson correlations test, Spear-
man test, partial correlations, and Mann Whitney test were used. 
 RESULTS 
 Validation of ANGPTL 3 and 4 ELISAs 
 The specifi city, sensitivity, and accuracy of the ANGPTL 
3 and 4 assays were determined. The standard curves for 
ANGPTL 3 and 4 ELISAs are presented in  Fig. 1A and B , 
respectively. The use of human serum or plasma resulted 
in similar values for both assays. The specifi city of the assays 
was confi rmed by testing the cross-reactivity with human 
recombinant ANGPTL 4 (RnD Systems) using ANGPTL3 
ELISA and with human recombinant ANGPTL3 (BioVen-
dor) using ANGPTL4 ELISA. No cross-reactivity was ob-
served. Sera derived from different mammalian species, 
mouse, rabbit, and bovine did not react in these assays. The 
detection limit of the assay was 1 ng/ml for ANGPTL3 and 
0.1 ng/ml for ANGPTL4. Intra- and inter-assay coeffi cients 
of variation were less than 10%. Serum samples from two 
 Expression of ANGPTL4 in cultured cells 
 Human ANGPTL4 cDNA cloned into pcDNA3.1 vector under 
the control of the cytomegalovirus (CMV) promoter-enhancer 
was a kind gift from Professor Sander Kersten (Wageningen Uni-
versity, The Netherlands). Human hepatocellular carcinoma cell 
line Huh7 (ATCC CCL-185) was transfected with pcDNA3.1 
(mock) or pcDNA3.1-ANGPTL4 using Lipofectamin 2000 (Invit-
rogen) according to the manufacturer’s instructions. Huh7 cells 
were seeded at 90% confl uence in 12-well plates a day before the 
transfection and grown in DMEM in the presence of 10% FBS. 
Cells were transiently transfected with 1.6 µg of expression plas-
mids and 4 µl of transfection reagent per well. Five h after the 
addition of transfection complexes, medium was replaced with 
serum free medium. Medium was collected after 48 h and centri-
fuged to remove cellular debris. Cells were washed with PBS (pH 
7.4) and then lysed in 175 µl of RIPA buffer [50 mM Tris, pH 8.0, 
150 mM NaCl, 1% (v/v) NP-40, 0.5% (v/v) sodium deoxycholate, 
0.1% SDS, and complete mini EDTA-free protease inhibitor 
cocktail (Roche Diagnostics GmbH, Mannheim, Germany)]. Cell 
lysate was transferred to 1.5 ml tubes prior to centrifugation for 
10 min at 15000  g . Aliquots from medium and cell lysate were 
subjected to SDS-PAGE and Western blot analysis. To evaluate 
the effect of heparin on the release of ANGPTL4, cells were incu-
bated with 100 IU/ml heparin for 1, 2, and 3 h. For Western blot 
analyses, cells were maintained after transfection in serum free 
medium containing 10 IU/ml of heparin for 48 h. One h before 
cell harvest, another 10 IU/ml of heparin were added to boost up 
the release. The viability and attachment of the cells were care-
fully evaluated by light microscopy and no effect of heparin at 
the concentrations used was observed. 
 SDS-PAGE and immunoblot analysis 
 Equivalent amounts of protein (25µg) from the cell lysate and 
medium (50 µl medium, concentrated by evaporation) were 
mixed with the reducing sample buffer and boiled in water for 5 
min. Samples were loaded on 12.5% SDS-polyacrylamide gels 
and transferred to nitrocellulose membranes. Membranes were 
incubated in TBST buffer (1 × TBS [pH 7.4] and 0.05% Tween 
20) with 5% fat free milk for 1 h at room temperature before ad-
dition of the primary antibodies. Primary antibodies were diluted 
in TBST buffer (1: 1000) and incubated with membranes for 40 
min at room temperature. Membranes were washed 4 × 15 min 
with TBST buffer. As a primary antibody, a rabbit affi nity purifi ed 
IgG raised against the region 26–229 of human ANGPTL4 (Bio-
Vendor) was used. HRP-conjugated donkey antigoat IgG (Santa-
Cruz) or goat anti-rabbit IgG (BioRad) were diluted (1: 10000 
and 1: 2000 respectively) in TBST-5% fat free milk and incubated 
with membranes for 40 min at room temperature. Membranes 
were washed 4 × 15 min with TBST and visualized using chemilu-
minescence assay (GE Healthcare, Buckinghamshire, UK). 
 Heparin chromatography 
 Human plasma (115 ml) was recycled (fl ow rate, 1 ml/min) 
overnight at + 4°C in a 250-ml HiTrap heparin affi nity chromatog-
raphy column (Amersham Biosciences). The column was washed 
with 25 mM Tris-HCl buffer, pH 7.4, containing 1 mM EDTA at a 
fl ow rate of 5 ml/min. The bound material was eluted with sequen-
tial steps using buffers containing 0.5 M, 1 M, and 2 M NaCl (fl ow 
rate, 10 ml/min/fraction). The fractions were analyzed for 
ANGPTL 3 and 4 using the developed ELISAs as described above. 
 Statistical analysis 
 All statistical analyses were performed using SPSS version 16.0 
for Windows (SPSS, Inc.) and GraphPad Prism 4.03 (GraphPad 
Software, Inc.). Selected parameters were logarithmically trans-
 Fig.  1. Standard curves for ANGPTL 3 and 4 ELISAs. A: Standard 
curve for ANGPTL3 ELISA was constructed using a standardized 
human serum with a concentration of 400 ng/ml of ANGPTL3. 
The standard serum was diluted to obtain the following concentra-
tions 1.25, 2.5, 5, 10, 20, and 40 ng/ml of ANGPTL3. All analyzed 
serum samples fell within the standard curve range when diluted 
1:50. B: standard curve for ANGPTL4 ELISA was constructed using 
human recombinant protein at concentrations of 0.19, 0.39, 0.78, 
1.56, 3.12, 6.25, 12.5, and 25 ng/ml. Serum samples were diluted 1: 
10, 1: 20, or 1: 40 in order to fall within the range of the curve. A 
second order polynomial equation fi ts best for both standard 
curves (r 2 >0.99). 
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 To test the relationship between ANGPTL4 and BMI, 
we performed partial correlation analyses using as control 
variables age, WHR, waist circumference, FFA, CRP, and 
Hcy, all related to serum levels of ANGPTL4. When the 
data was then adjusted for age, FFA, and waist circumfer-
ence, serum ANGPTL4 displayed inverse correlations with 
BMI ( r = -0.172;  P = 0.008). In accordance with this, we 
observed that in subjects in the age range of 30–45 years 
the levels of ANGPTL4 were signifi cantly decreased ( P = 
0.03) in overweight subjects (8.8 ± 1.3 ng/ml, mean ± 
SEM, n = 23) as compared with values obtained in normal-
weight subjects (17.5 ± 2.9 ng/ml, mean ± SEM, n = 41) 
subjects were tested for dilution linearity (5- to 50-fold di-
lution range) and the mean coeffi cient of variation was 
14.1% for ANGPTL3 assay and 9.6% for ANGPTL4 assay. 
When increasing amounts of recombinant protein were 
added to serum, the average recovery was 113% for 
ANGPTL3 and 104% for ANGPTL4. No signifi cant differ-
ences of ANGPTL 3 and 4 concentrations were observed 
after three to six freezing/thawing cycles for two different 
human plasma samples. To further verify the ANGPTL3 
ELISA, we have quantifi ed 18 serum samples with our 
method and with the commercially available kit from Bio-
Vendor. The values obtained with our method (325 ± 114 
ng/ml, mean ± SD, n = 18) and commercial ELISA (418 ± 
136 ng/ml, mean ± SD, n = 18) were highly correlated ( r = 
0.96,  P < 0.0001, data not shown). 
 Characteristics of the study population 
 The study population consisted of 125 male and 125 fe-
male subjects with the mean age of 55 years. The age, body 
mass index (BMI), TG, LDL-C, apoB, insulin, HOMA-IR, 
CRP, and Hcy values did not differ signifi cantly between 
genders. A signifi cant gender difference was observed for 
waist-hip ratio (WHR), FFA, TC, HDL-C, apoA-I, and glu-
cose concentrations (for all,  P < 0.05). Serum ANGPTL3 
levels demonstrated high variability in the population with 
an average value (± SD) of 368 ± 168 ng/ml. The distribu-
tion in the population was skewed to the left and normal-
ized after logarithmic transformation. Also, ANGPTL4 
serum levels were highly variable between individuals with 
values ranging from 2 to 158 ng/ml. No gender differ-
ences were observed for ANGPTL 3 or 4 ( Table 1 ). 
 Correlation of ANGPTL 3 and 4 with clinical and 
biochemical parameters 
 As depicted in  Table 2 , bivariate correlations revealed a 
positive association of serum ANGPTL3 with age ( r = 0.292, 
 P < 0.001), HDL-C ( r = 0.224,  P < 0.001), and apoA-I 
( r = 0.144,  P = 0.023) and a negative correlation with TG 
( r = -0.182,  P = 0.004) and apoB/apoA-I ratio ( r = -0.192, 
 P = 0.002). The observed correlations remained signifi cant 
after adjustment for age, gender, and BMI. However, when 
HDL-C and apoA-I levels were used as control variables, 
the correlation of ANGPTL3 with triglycerides was com-
pletely lost ( r = -0.029,  P = 0.649). Furthermore, we have 
divided the study population in quartiles for TG levels and 
for HLD-C levels. When analyzing quartiles, a signifi cant 
decrease ( P < 0.0001) of ANGPTL3 levels in subjects with 
high TG and low HDL-C (75th TG/25th HDL, n = 36) 
compared with subjects with low TG and high HDL-C 
(25th TG/ 75th HDL, n = 33) ( Fig. 2 ) was observed. 
 Serum ANGPTL4 levels were positively correlated with 
age ( r = 0.178,  P = 0.013), WHR ( r = 0.155,  P = 0.016), FFA 
( r = 0.129,  P = 0.044), and CRP ( r = 0.177,  P = 0.002) and 
negatively with Hcy ( r = -0.136,  P = 0.034) ( Table 1 ). Be-
cause the ANGPTL4 distribution was still slightly skewed 
after the logarithm transformation, we also used nonpara-
metric tests to verify the results. The Spearman test re-
vealed the signifi cant correlations for the same parameters 
that were obtained with the Pearson test. 
 TABLE 1. Characteristics of the study population 
Parameter
Males, n = 125 
(mean ± SD)
Females, n = 125 
(mean ± SD)  p 
Age (years) 55.29  ± 15.29 54.94  ± 15.13 0.855
BMI (kg/m 2 ) 25.62  ± 3.11 26.58  ± 4.72 0.060
WHR 0.95  ± 0.05 0.85  ± 0.05  <0.001 
FFA (µmols/l) 392.17  ± 203.65 575.32  ± 256.70  <0.001 
TC (mmol/l) 5.45  ± 1.07 5.80  ± 0.93  0.006 
TG (mmol/l) 1.54  ± 1.31 1.40  ± 0.65 0.276
LDL-C (mmol/l) 3.52  ± 0.91 3.69  ± 0.81 0.123
apoB (g/l) 1.12  ± 0.26 1.15  ± 0.24 0.368
HDL-C (mmol/l) 1.25  ± 0.35 1.47  ± 0.38  <0.001 
apoA-I (g/l) 1.47  ± 0.27 1.67  ± 0.28  <0.001 
apoB/apoA-I 0.78  ± 0.22 0.70  ± 0.19  0.003 
Glucose (mmol/l) 5.61  ± 0.82 5.32  ± 0.62  0.002 
Insulin (mU/l) 7.94  ± 8.34 7.45  ± 4.85 0.572
HOMA IR 2.03  ± 2.29 1.85  ± 1.49 0.469
CRP (mg/l) 2.85  ± 7.73 2.09  ± 5.44 0.399
Hcy (µmol/l) 12.47  ± 5.23 12.45  ± 4.86 0.976
ANGPTL3 (µg/l) 347.88  ± 159.43 388.60  ± 204.12 0.080
ANGPTL4 (µg/l) 20.70  ± 25.77 16.33  ± 20.62 0.142
 P- values under 0.05 were considered signifi cant and highlighted in 
the table using bold font . 
 TABLE 2. Correlations of ANGPTL 3 and 4 with clinical and 
biochemical parameters 
Parameter
Correlations with
ANGPTL3
Correlations with
ANGPTL4
Pearson 
Correlation
Signifi cance
(2-tailed)
Pearson 
Correlation
Signifi cance
(2-tailed)
Age (years)  0.292  <0.001  0.178  0.005 
BMI (kg/m 2 )   0.071 0.263 0.061 0.343 a 
WHR   0.077 0.231  0.155  0.016 
FFA (µmols/l) 0.099 0.118  0.129  0.044 
TC (mmol/l) 0.040 0.527   0.046 0.471
TG (mmol/l)  -0.182  0.004 b   0.049 0.441
LDL-C (mmol/l) 0.040 0.527   0.046 0.471
apoB (g/l)   0.122 0.054   0.092 0.152
HDL-C (mmol/l)  0.224  <0.001 0.048 0.457
apoA-I (g/l)  0.144  0.023 0.011 0.860
apoB/apoA-I  -0.192  0.002   0.081 0.208
Glucose (mmol/l)   0.006 0.931 0.046 0.470
Insulin (mU/l) 0.083 0.191   0.028 0.664
HOMA IR 0.070 0.270   0.037 0.560
CRP (mg/l)   0.002 0.978  0.177  0.008 
Hcy (µmol/l)   0.105 0.096  -0.136  0.034 
 P- values under 0.05 were considered signifi cant and highlighted in 
the table using bold font . 
 a When the data was adjusted for age, waist circumference, and 
FFA a negative correlation of serum ANGPTL4 and BMI was observed 
( r =   0.172;  P = 0.008).
 b If HDL-C and apoA-I levels were used as control variables the 
observed correlation of ANGPTL3 with triglycerides is completely lost 
( r =   0.029,  P = 0.649).
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828 Journal of Lipid Research Volume 51, 2010
that the transient overexpression of ANGPTL4 in Huh7 
cells for 48 h resulted in the release of full length, C- and 
N-terminal fragments of ANGPTL4 into the growth me-
dium ( Fig. 5B ). Addition of heparin to the growth medium 
resulted in increased release of all three forms of ANGPTL4 
to the medium after 48 h ( Fig. 5C ). Following shorter in-
cubation times (1, 2, and 3 h) no indication of ANGPTL4 
cleavage, neither in the medium nor in the cells, could be 
demonstrated using Western blot (data not shown). 
 To further verify the interaction between ANGPTL 3 and 
4 with heparin, we analyzed human plasma using heparin 
affi nity chromatography. Human plasma containing 83 
ng/ml ANGPTL3 and 4.6 ng/ml ANGPTL4 were recycled 
overnight on the column at + 4°C. Using the ELISAs, we 
quantifi ed ANGPTL 3 and 4 in the nonbound fraction and 
fractions eluted with 0.5M, 1M and 2M NaCl. The percent-
age of recovery was 98% for ANGPTL3 (10% in the non-
bound fraction and 88% in 0.5 M NaCl fraction) and 64% 
for ANGPTL4 (12% in the nonbound fraction, 50% in 0.5 
M NaCl fraction and 3% in 1 M NaCl fraction) ( Fig. 6 ). 
 DISCUSSION 
 The present study reports on the serum concentrations 
of ANGPTL 3 and 4 in a Finnish human population sam-
ple using quantitative ELISAs. Our measurements were in 
( Fig. 3 ). No differences in physical activity between the 
normal-weight subjects (37.2% had ideal and suffi cient 
physical activity) and overweight subjects (39.2% had ideal 
and suffi cient physical activity) were observed. No signifi cant 
differences were observed in the other age groups (group 2: 
45–60 years,  P = 0.62; group 3: 60–94 years,  P = 0.28). 
 No correlation between the serum levels of ANGPTL 3 
and 4 was evident. 
 Effect of heparin on human ANGPTL 3 and 4 in vivo and 
in vitro 
 To test whether ANGPTL 3 and 4 interact with the en-
dothelial surface, we quantifi ed both proteins in pre- and 
post-heparin plasma. Kinetic measurements revealed that 
5–15 min after heparin injection are optimal to assess the 
release of ANGPTL4 ( Fig. 4A ). Injection of 100 IU/kg 
body weight heparin increased the levels of both ANGPTL 
3 and 4 in post-heparin plasma from all subjects studied 
( Fig. 4B, C ). 
 To test whether ANGPTL4 interact with the surface pro-
teoglycans in vitro, we tested the effect of adding heparin 
to the growth medium of Huh7 cells overexpressing 
ANGPTL4. Addition of 100 IU/ml heparin to the culture 
medium induced an increase in the release of ANGPTL4 
to the culture medium and a concomitant decrease of cel-
lular ANGPTL4 ( Fig. 5A , B ). Western blot analyses showed 
 Fig.  2. Serum ANGPTL3 concentration in subjects classifi ed ac-
cording to HDL-C and TG levels. The study population was divided 
in quartiles based on TG and HDL-C levels. Levels of ANGPTL3 
were compared in subjects with high TG and low HDL-C (75th 
TG/25th HDL, n = 36) and in subjects with low TG and high HDL-
C (25th TG/ 75th HDL, n = 33). The difference in ANGPTL3 levels 
between these two groups was highly signifi cant ( P < 0.0001) as 
measured by the Mann Whitney test. The values represent mean ± 
SEM. 
 Fig.  3. ANGPTL4 concentration in normal and overweight sub-
jects. ANGPTL4 levels were compared in subjects, age 30–45 years, 
with normal weight (BMI < 25, n = 41) or overweight (BMI > 25, 
n = 23). The values represent mean ± SEM. Signifi cance was tested 
using the Mann Whitney test ( P = 0.03). 
 Fig.  4. ANGPTL 3 and 4 in pre- and post-heparin plasma. 
ANGPTL4 was measured in plasma collected at baseline (0 min-
utes) and 5, 10, 15, 30, and 60 min after a heparin injection (100 
IU/kg body weight) from three subjects (A). ANGPTL3 (B) and 
ANGPTL4 (C) were measured in preheparin plasma (Plasma) and 
in post-heparin plasma (PHP) collected 15 min after the injection 
of heparin (100 IU/kg body weight) from 7 different subjects. 
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ing TG and low HDL-C,  b ) low levels of ANGPTL4 are as-
sociated with increased body weight, and  c ) both ANGPTL 
3 and 4 are increased in post-heparin plasma. 
 Genetic and in vitro studies have suggested an inhibi-
tory effect of human ANGPTL 3 and 4 on LPL activity and 
thereby, have an increasing effect on circulating TG levels 
( 9–11 ). One therefore could expect that high levels of 
ANGPTL 3 and 4 in the circulation would be associated 
with high TG levels. Our observation that serum ANGPTL 
3 and 4 are not positively correlated with fasting TG con-
centration was therefore somewhat surprising. However, 
this cannot exclude that ANGPTL 3 and 4 would not in-
hibit LPL in humans. A possible explanation for the lack 
of correlation between ANGPTL 3 and 4 and TG levels 
could be that the functional fractions of these proteins do 
not reside in the circulation but may exist bound to the 
endothelial surface that is the actual site for LPL-mediated 
lipolysis of TG-rich lipoproteins ( 24 ). LPL is synthesized 
and secreted via adipocytes, macrophages, and muscle 
cells and thereafter associated with the vascular endo-
thelium through heparin sulfate proteoglycans and the 
glycosylphosphatidylinositol-anchored high density lipo-
protein-binding protein 1 from where it can be released in 
circulation with heparin treatment ( 25, 26 ). We demon-
strated here that intravenous injection of heparin also in-
duces release of ANGPTL 3 and 4 and that the levels of 
circulating and endothelial bound ANGPTLs may differ 
between individuals. There are several basic residue-rich 
regions in ANGPTL 3 and 4, both in N- and C-terminal 
regions that could mediate the binding of these proteins 
at the sites important for LPL activity. For ANGPTL3, 
good agreement with previous reports showing that 
ANGPTL3 is present in the circulation at a higher concen-
tration (224 ng/ml) compared with ANGPTL4 (1.73 ng/
ml) ( 22, 23 ). Although some differences exist in the values 
reported for ANGPTL 3 and 4, these probably are due to 
differences in method standardization, population sam-
ples, and/or the antibodies used. Based on our ANGPTL3 
and 4 determinations, major fi ndings of our study are:  a ) 
low levels of ANGPTL3 are associated with high circulat-
 Fig.  5. Effect of heparin on the release of ANGPTL4 from Huh7 
cells. The release of ANGPTL4 from Huh7 cells overexpressing hu-
man ANGPTL4 was quantifi ed by ELISA in the medium (A) and 
cells (B) grown in the absence (Control) or presence of 100 IU/ml 
heparin (Heparin) for 1, 2, and 3 h. Bars represent mean ± SD of 
triplicate samples. C: Analysis of growth medium and cells by im-
munoblot to evaluate the effect of heparin after 48 h on the release 
of ANGPTL4 from Huh7 cells overexpressing human ANGPTL4 
protein using a polyclonal anti-ANGPTL4 antibody. 
 Fig.  6. Interaction of ANGPTL 3 and 4 with heparin. Human 
plasma was subjected to heparin affi nity chromatography and step-
wise eluted with buffer containing increasing concentrations of 
NaCl. ANGPTL3 (A) and ANGPTL4 (B) were measured by ELISA 
in plasma loaded to the column (Put On), in the nonbound frac-
tions (Non Bound) and in elution fractions with increasing salt 
concentrations (0.5M NaCl, 1M NaCl and 2M NaCl). Bars repre-
sent the total amount of ANGPTL 3 and 4. 
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pose tissue. Indeed, ANGPTL4 is required for a normal 
development of lymphatic system in mice ( 31 ). It will be of 
major interest to study whether elevated levels of ANGPTL4 
maintain the integrity of lymphatic vessels and stimulate 
drainage of lipids from adipose tissue. 
 Additionally to the aforementioned points, careful data 
analyses reveal a signifi cant correlation of ANGPTL4 with 
age, WHR, plasma FFA, CRP, and Hcy. The positive asso-
ciation between FFA and plasma ANGPTL4 was previously 
reported ( 21, 23 ). Our data confi rm these results and 
strengthen them via the observed association with WHR. 
The strong relationship of circulating FFA with upper-
body obesity is well known ( 32 ). Furthermore, we report 
that ANGPTL4, as well as ANGPTL3, increase with age. 
This is very interesting because it is recognized that there 
is a selective decrease in the   -adrenergic lipolytic capacity 
with aging ( 33 ). We cannot exclude the possibility that an 
increased synthesis of ANGPTL3 and 4 in adipose tissue 
would compensate for the decreased mobilization of fat in 
older individuals. In fact, this could explain why there is 
no signifi cant decrease of ANGPLT4 in overweight sub-
jects over 45 years old as observed in overweight subjects 
under 45 years old. The inverse relationship of ANGPTL4 
with Hcy is not surprising as ANGPTL4 was shown to de-
crease key enzymes in the methionine/Hcy metabolic cy-
cle ( 34 ). The positive correlation with CRP suggests that 
infl ammatory processes may be connected to increased 
ANGPTL4 levels in humans. 
 Although our study provides important and novel infor-
mation, it is also subjected to limitations because our sam-
ple size was small, we did not determine the tissue-specifi c 
protein levels, and we did not measure the concentrations 
of N- and C-terminal fragments for ANGPTL 3 and 4. 
 To conclude, we have developed and validated two 
quantitative ELISAs to measure human ANGPTL 3 and 4. 
Using these methods, we have demonstrated that a de-
crease of serum ANGPTL3 is associated with a decrease in 
HDL-C and an increase in TGs whereas low serum 
ANGPTL4 is associated with increased body weight. These 
observations further strengthen the important role of 
ANGPTL 3 and 4 in the modulation of serum TG and 
HDL levels as well as in human obesity.  
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